Short Interest in Gilead Sciences, Inc. (GILD) Declines By 14.0%

Gilead Sciences, Inc. (NASDAQ:GILD) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 11,548,612 shares, a drop of 14.0% from the January 15th total of 13,429,498 shares. Approximately 0.9% of the company’s shares are short sold. Based on an average trading volume of 7,327,632 shares, the short-interest ratio is presently 1.6 days.

Shares of GILD opened at $65.94 on Thursday. Gilead Sciences has a 52 week low of $60.32 and a 52 week high of $82.71. The company has a market cap of $87.28 billion, a P/E ratio of 10.72, a P/E/G ratio of 66.65 and a beta of 1.19. The company has a current ratio of 3.36, a quick ratio of 3.29 and a debt-to-equity ratio of 1.09.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Monday, February 4th. The biopharmaceutical company reported $1.44 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The business’s revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.78 earnings per share. On average, equities research analysts predict that Gilead Sciences will post 6.23 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 28th. Shareholders of record on Friday, March 15th will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 3.82%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.57. The ex-dividend date is Thursday, March 14th. Gilead Sciences’s payout ratio is currently 37.07%.

In other news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $71.20, for a total value of $3,560,000.00. Following the transaction, the director now directly owns 2,877,762 shares of the company’s stock, valued at $204,896,654.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 1.16% of the company’s stock.

Hedge funds have recently bought and sold shares of the business. Athena Capital Advisors LLC bought a new stake in Gilead Sciences in the fourth quarter worth approximately $27,000. Advisors Preferred LLC bought a new stake in Gilead Sciences in the fourth quarter worth approximately $31,000. Legacy Financial Advisors Inc. grew its position in Gilead Sciences by 361.3% in the fourth quarter. Legacy Financial Advisors Inc. now owns 489 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 383 shares in the last quarter. We Are One Seven LLC bought a new stake in Gilead Sciences in the fourth quarter worth approximately $37,000. Finally, Larson Financial Group LLC bought a new stake in Gilead Sciences in the fourth quarter worth approximately $38,000. 80.03% of the stock is owned by institutional investors.

GILD has been the topic of several analyst reports. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Cantor Fitzgerald lifted their target price on shares of Gilead Sciences from $87.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, October 26th. Piper Jaffray Companies downgraded shares of Gilead Sciences from an “overweight” rating to a “neutral” rating and dropped their target price for the stock from $85.00 to $75.00 in a research report on Friday, October 26th. Barclays lifted their target price on shares of Gilead Sciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, October 26th. Finally, Raymond James lowered their price objective on shares of Gilead Sciences from $97.00 to $94.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 26th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $84.01.

WARNING: “Short Interest in Gilead Sciences, Inc. (GILD) Declines By 14.0%” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2019/02/14/short-interest-in-gilead-sciences-inc-gild-declines-by-14-0.html.

About Gilead Sciences

Gilead Sciences, Inc discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Earnings Reports

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit